MENU
+Compare
HALO
Stock ticker: NASDAQ
AS OF
Oct 8, 04:59 PM (EDT)
Price
$65.19
Change
-$0.83 (-1.26%)
Capitalization
7.72B

HALO Halozyme Therapeutics Forecast, Technical & Fundamental Analysis

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more

Industry: #Biotechnology
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for HALO with price predictions
Oct 07, 2025

HALO's RSI Oscillator remains in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 324 cases, the price rose further within the following month. The odds of a continued upward trend are .

HALO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 295 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HALO as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HALO turned negative on September 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .

HALO moved below its 50-day moving average on October 03, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HALO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.202) is normal, around the industry mean (23.421). P/E Ratio (15.108) is within average values for comparable stocks, (54.441). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.237). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (7.148) is also within normal values, averaging (342.085).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

View a ticker or compare two or three
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

HALO is expected to report earnings to rise 4.55% to $1.61 per share on November 10

Halozyme Therapeutics HALO Stock Earnings Reports
Q3'25
Est.
$1.61
Q2'25
Beat
by $0.30
Q1'25
Beat
by $0.13
Q4'24
Beat
by $0.11
Q3'24
Beat
by $0.31
The last earnings report on August 05 showed earnings per share of $1.54, beating the estimate of $1.24. With 639.25K shares outstanding, the current market capitalization sits at 7.72B.
A.I. Advisor
published General Information

General Information

a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12390 El Camino Real
Phone
+1 858 794-8889
Employees
373
Web
https://www.halozyme.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTDDX39.71N/A
N/A
Invesco Emerging Markets ex-China A
HMDCX26.05N/A
N/A
Hartford MidCap C
ASICX28.46N/A
N/A
Invesco Asia Pacific Equity C
ZDIIX28.21N/A
N/A
Zacks Dividend Institutional
NPFCX68.69-0.39
-0.56%
American Funds New Perspective C

HALO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
-1.42%
AXON - HALO
47%
Loosely correlated
-0.97%
XENE - HALO
44%
Loosely correlated
-0.99%
IRON - HALO
38%
Loosely correlated
-2.01%
TECH - HALO
35%
Loosely correlated
-4.41%
ARGX - HALO
35%
Loosely correlated
+1.19%
More